Insider Transactions in Q1 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.93%
|
$530,000
$53.81 P/Share
|
|
Jan 27
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
102,664
-13.17%
|
$5,749,184
$56.04 P/Share
|
|
Jan 27
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
102,664
+15.4%
|
$1,231,968
$12.29 P/Share
|
|
Jan 27
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.35%
|
$1,650,000
$55.66 P/Share
|
|
Jan 27
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
5,000
-12.99%
|
$285,000
$57.03 P/Share
|
|
Jan 27
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.41%
|
$76,000
$19.87 P/Share
|
|
Jan 27
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
31,250
-5.44%
|
$1,718,750
$55.78 P/Share
|
|
Jan 27
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+7.48%
|
$625,000
$20.49 P/Share
|
|
Jan 24
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,064
+14.16%
|
$258,384
$6.36 P/Share
|
|
Jan 23
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+6.28%
|
$0
$0.62 P/Share
|
|
Jan 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
14,000
-7.6%
|
-
|
|
Jan 02
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.38%
|
$280,000
$28.03 P/Share
|